Mallinckrodt (MNK) PT Lowered to $22.00 at Mizuho

Mallinckrodt (NYSE:MNK) had its price target decreased by research analysts at Mizuho from $25.00 to $22.00 in a research note issued on Thursday, The Fly reports. The firm presently has a “neutral” rating on the stock. Mizuho’s target price would suggest a potential upside of 45.12% from the company’s previous close.

Other research analysts have also recently issued research reports about the company. SunTrust Banks set a $20.00 target price on Mallinckrodt and gave the company a “hold” rating in a research report on Tuesday. ValuEngine lowered Mallinckrodt from a “sell” rating to a “strong sell” rating in a research note on Monday. Canaccord Genuity set a $40.00 price target on Mallinckrodt and gave the company a “buy” rating in a research note on Monday, March 18th. Finally, Morgan Stanley set a $32.00 price target on Mallinckrodt and gave the company a “hold” rating in a research note on Thursday, February 28th. Four research analysts have rated the stock with a sell rating, eight have issued a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. Mallinckrodt currently has an average rating of “Hold” and a consensus target price of $30.44.

MNK stock traded down $0.16 during trading hours on Thursday, hitting $15.16. 1,356,921 shares of the stock were exchanged, compared to its average volume of 1,994,610. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.45 and a quick ratio of 1.08. The stock has a market capitalization of $1.27 billion, a price-to-earnings ratio of 1.89, a PEG ratio of 0.15 and a beta of 2.12. Mallinckrodt has a 12 month low of $13.45 and a 12 month high of $36.65.

Mallinckrodt (NYSE:MNK) last posted its quarterly earnings data on Tuesday, May 7th. The company reported $1.94 earnings per share for the quarter, topping the consensus estimate of $1.73 by $0.21. The firm had revenue of $791.00 million for the quarter, compared to analysts’ expectations of $766.27 million. Mallinckrodt had a positive return on equity of 14.22% and a negative net margin of 118.53%. The company’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same quarter last year, the business earned $1.31 EPS. Research analysts expect that Mallinckrodt will post 8.4 EPS for the current year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. QS Investors LLC grew its holdings in Mallinckrodt by 14.3% during the fourth quarter. QS Investors LLC now owns 4,000 shares of the company’s stock worth $64,000 after buying an additional 500 shares in the last quarter. Sheaff Brock Investment Advisors LLC lifted its position in shares of Mallinckrodt by 4.6% during the 4th quarter. Sheaff Brock Investment Advisors LLC now owns 13,440 shares of the company’s stock valued at $212,000 after buying an additional 594 shares during the last quarter. Martingale Asset Management L P lifted its position in shares of Mallinckrodt by 0.8% during the 4th quarter. Martingale Asset Management L P now owns 76,053 shares of the company’s stock valued at $1,202,000 after buying an additional 597 shares during the last quarter. Retirement Systems of Alabama lifted its holdings in Mallinckrodt by 0.6% during the 1st quarter. Retirement Systems of Alabama now owns 108,703 shares of the company’s stock worth $2,363,000 after purchasing an additional 685 shares in the last quarter. Finally, Arizona State Retirement System lifted its holdings in Mallinckrodt by 1.2% during the 4th quarter. Arizona State Retirement System now owns 59,797 shares of the company’s stock worth $945,000 after purchasing an additional 714 shares in the last quarter.

Mallinckrodt Company Profile

Mallinckrodt plc, together with its subsidiaries, develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands, and Specialty Generics and Amitiza.

Read More: What are the benefits of buying treasury bonds?

The Fly

Analyst Recommendations for Mallinckrodt (NYSE:MNK)

Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.